Molecular determinants and modifiers of Matrin-3 toxicity, condensate dynamics, and droplet morphology

Highlights
- Matrin-3 forms liquid, dynamic, shell-like nuclear condensates in yeast.
- Disease-associated mutations in Matrin-3 impair condensate dynamics and morphology.
- Proteotoxicity of Matrin-3 in yeast is driven by its RNA-recognition motifs.
- Potentiated Hsp104 variants can suppress the toxicity of Matrin-3 WT and mutants.
Molecular determinants and modifiers of Matrin-3 toxicity, condensate dynamics, and droplet morphology

Macy L. Sprunger,1 Ken Lee,1 Brian S. Sohn,1 and Meredith E. Jackrel1,2,*

SUMMARY
Matrin-3 (MATR3) is a DNA- and RNA-binding protein implicated in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and distal myopathy. Here, we report the development of a yeast model of MATR3 proteotoxicity and aggregation. MATR3 is toxic and forms dynamic shell-like nuclear condensates in yeast. Disease-associated mutations in MATR3 impair condensate dynamics and disrupt condensate morphology. MATR3 toxicity is largely driven by its RNA-recognition motifs (RRMs). Further, deletion of one or both RRMs drives coalescence of these condensates. Aberrant phase separation of several different RBPs underpins ALS/FTD, and we have engineered Hsp104 variants to reverse this misfolding. Here, we demonstrate that these same variants also counter MATR3 toxicity. We suggest that these Hsp104 variants which rescue MATR3, TDP-43, and FUS toxicity might be employed against a range of ALS/FTD-associated proteins. We anticipate that our yeast model could be a useful platform to screen for modulators of MATR3 misfolding.

INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder which results in the degeneration of upper and lower motor neurons, leading to atrophy of the skeletal muscles, and ultimately paralysis and death (Ling et al., 2013; Robberecht and Philips, 2013; Taylor et al., 2016). Frontotemporal dementia (FTD) is a related disorder which affects the frontal and temporal cortices, leading to personality, behavioral, and language changes (Ling et al., 2013). ALS and FTD lie within a disease spectrum, with clinical, pathological, and genetic overlap (Ling et al., 2013; Robberecht and Philips, 2013; Taylor et al., 2016). The implication of multiple RNA-binding proteins (RBPs) in ALS/FTD, including TDP-43 (Neumann et al., 2006), FUS (Kwiatkowski et al., 2009; Vance et al., 2009), hnRNP A1 (Kim et al., 2013), hnRNP A2/B1 (Kim et al., 2013), EWSR1 (Couthouis et al., 2012; Neumann et al., 2011), TAF15 (Couthouis et al., 2011; Neumann et al., 2011), ATXN2 (Elden et al., 2010), and MATR3 (Johnson et al., 2014), suggests that RNA dysregulation is a key mechanism underpinning ALS/FTD pathogenesis (King et al., 2012). These RBPs are also characterized by the presence of large intrinsically disordered regions (IDRs) which can drive liquid-liquid phase separation (LLPS) (Franzmann and Alberti, 2019; Sprunger and Jackrel, 2021). Because of their disordered nature and their accumulation at high concentrations upon LLPS, these RBPs are prone to misfold and aggregate, and accumulations of misfolded RBPs are the pathological hallmark of ALS/FTD (Ling et al., 2013; Taylor et al., 2016).

Matrin-3 (MATR3) is a DNA- and RNA-binding nuclear matrix protein which is highly conserved (Belgrader et al., 1991). MATR3 functions in the DNA damage response, transcription, splicing, RNA degradation, mRNA export, and maintenance of the nuclear framework through interactions with nuclear laminas (Boehringer et al., 2017; Coelho et al., 2015; Depreux et al., 2015; Hibino et al., 2000; Leonard et al., 2003; Salton et al., 2010, 2011; Zeitz et al., 2009). A missense mutation, MATR3S85C, leads to autosomal dominant distal myopathy with vocal cord and pharyngeal weakness (VCPDM), many cases of which have subsequently been reclassified as ALS (Feit et al., 1998; Johnson et al., 2014; Senderek et al., 2009). Exome sequencing has identified 13 additional MATR3 mutations in familial ALS and ALS/FTD cases (Johnson et al., 2014; Leblond et al., 2016; Lin et al., 2015; Marangi et al., 2017; Narain et al., 2019; Origone et al., 2015). Wild-type MATR3 displays physiological granular nuclear staining in neurons with more intense nuclear staining and some diffuse cytoplasmic redistribution in ALS patient neurons (Johnson et al., 2014). In ALS patients with mutations in FUS, and in those harboring the C9orf72 hexanucleotide repeat expansion, pathological inclusions of wild-type MATR3 have been noted (Johnson et al., 2014; Tada et al., 2018). Further, MATR3...
has been found to colocalize with TDP-43 inclusions in a significant subset of patient samples (Tada et al., 2018). Although MATR3 mutations have a low frequency, the pathology of both mutant and wild-type MATR3 in diverse forms of ALS/FTD suggests that MATR3 could play a key role in pathogenesis.

The role of MATR3 and its pathogenic mutations have recently been investigated in several model systems (Gallego-Iradi et al., 2015; Kao et al., 2020; Malik et al., 2018; Mensch et al., 2018; Moloney et al., 2018; Ramesh et al., 2020; van Bruggen et al., 2021; Zhang et al., 2019). Homozygous knockout of MATR3 in mice is embryonic lethal, suggesting that MATR3 is essential for development (Quintero-Rivera et al., 2015). Overexpression of MATR3WT, MATR3S85C, or MATR3F115C as well as knock-in of MATR3S85C in mice results in motor and neuronal defects (Kao et al., 2020; Moloney et al., 2018; Zhang et al., 2019). However, knock-in of MATR3F115C did not lead to muscle or neuronal pathology in mice, suggesting that MATR3F115C may not be a causative mutation in ALS/FTD (van Bruggen et al., 2021). Expression of MATR3WT in primary neurons and Drosophila is associated with increased risk of death or shortened lifespan, and disease-associated mutations to MATR3 subtly enhance this effect (Malik et al., 2018; Ramesh et al., 2020; Zhao et al., 2020).

In myoblasts and neurons, MATR3 mutants did not show altered nucleocytoplasmic localization or protein expression levels (Gallego-Iradi et al., 2015; Malik et al., 2018; Mensch et al., 2018). RNA-binding deficient MATR3 can undergo LLPS with localization to large nuclear puncta, and introduction of S85C to RNA-binding deficient MATR3 constructs decreases condensate dynamics (Gallego-Iradi et al., 2019; Iradi et al., 2018; Malik et al., 2018; Mensch et al., 2018). While much has been learned about MATR3, there have been some conflicting findings and many key questions remain unresolved. For instance, in primary neurons, it was shown that MATR3 zinc fingers drive toxicity, while conflicting results in a Drosophila model suggest that MATR3 RRRs drive toxicity (Malik et al., 2018; Ramesh et al., 2020).

While recent studies have revealed important insights into MATR3 function, key gaps remain regarding the link between MATR3 and ALS/FTD pathology. A simple, genetically tractable model with exogenous MATR3 expression would be useful for investigating the contribution of MATR3 domains and mutations to MATR3 toxicity, aggregation, and liquid-liquid phase separation. Here, we have developed a budding yeast, Saccharomyces cerevisiae, model system to investigate the molecular determinants of MATR3 proteotoxicity. Numerous pathways relevant to human disease are highly conserved in S. cerevisiae, and yeast models have proven useful in studying diverse human disorders including ALS/FTD (Elden et al., 2010; Johnson et al., 2008; Ju et al., 2011; Khurana and Lindquist, 2010; Ryan et al., 2019; Sun et al., 2011; Treusch et al., 2011). We find that overexpression of MATR3 in yeast recapitulates key features of MATR3 expression in other systems, including nuclear localization and toxicity. Using this system we find that MATR3 forms dynamic shell-like nuclear condensates, and that the formation of these structures is impaired upon introduction of ALS/FTD-associated mutations in MATR3. By studying a series of MATR3 constructs, we delineate key sequence-specific elements driving MATR3 toxicity, localization, aggregation, and phase separation. Furthermore, we demonstrate that engineered Hsp104 variants that can suppress the toxicity and mislocalization of TDP-43 and FUS (Jackrel et al., 2014; Jackrel and Shorter, 2014a; Yokom et al., 2016) can also suppress the toxicity induced by MATR3 and its mutants, thereby simultaneously countering the misfolding of three different proteins which may misfold together in ALS/FTD patients. Our results suggest that MATR3 toxicity arises from aberrant protein misfolding and consequent proteotoxic stress. We therefore propose that this yeast model of MATR3 can be utilized as a platform for studying the underpinnings of MATR3 toxicity, and for screening for modulators of MATR3 phase separation and toxicity. Further, we suggest that engineered Hsp104 variants could be employed to simultaneously combat a range of proteins that misfold in ALS/FTD, including MATR3.

**RESULTS**

Matrin-3 is an intrinsically disordered RNA-binding protein that is toxic when overexpressed in yeast

MATR3 is a nuclear matrix protein that is 847 amino acids long. MATR3 contains two zinc finger (ZF) motifs, two RNA-recognition motifs (RRMs), and a nuclear localization signal (NLS) (Malik et al., 2018) (Figure 1A). The FoldIndex algorithm (Prilusky et al., 2005), which analyzes hydrophobicity and net charge per residue, predicts that most regions outside of these annotated domains are unfolded (Figure 1B). Fourteen different pathogenic mutations have been identified in MATR3, including S85C, F115C, P154S, and T622A, each of which are implicated in familial ALS/FTD, although it remains controversial if the F115C mutation drives ALS/FTD (Johnson et al., 2014; Leblond et al., 2016; Lin et al., 2015; Marangi et al., 2017; Origone et al., 2015; Senderek et al., 2009; van Bruggen et al., 2021; Xu et al., 2016). Most of these pathogenic...
Figure 1. MATR3 is an intrinsically disordered protein that is toxic in yeast but does not display prion-like properties

(A) Domain map of MATR3. The zinc finger (ZF) domains, RNA-recognition motifs (RRMs), and nuclear localization signal (NLS) are highlighted. Mutations of interest in MATR3 are shown, with mutations used in this study displayed in bold. Asterisk indicates a patient-associated mutation which may not be causative of disease.

(B) Computational analysis of MATR3 sequence using the FoldIndex algorithm (pink and dark pink), and PLAAC algorithm (teal) (Lancaster et al., 2014; Prilusky et al., 2005). The output score of each program is plotted against the MATR3 sequence. FoldIndex uses net charge per residue and hydrophobicity to predict whether a region is folded (positive, pink) or unfolded (negative, dark pink). This analysis predicts the presence of large disordered regions throughout the MATR3 sequence. PLAAC analyzes amino acid composition to identify regions of similar composition to known yeast prion proteins, with prion-like domains indicated by a score of one (Lancaster et al., 2014). By this analysis, MATR3 is not predicted to have a prion-like domain.

(C) W303WT and W303Δhsp104 yeast were transformed with the indicated pAG413GAL-MATR3 variant or vector control. Strains were serially diluted 5-fold and spotted in duplicate onto glucose (non-inducing) and galactose (inducing) media. Scores are based on number of spots from an average of at least three biological replicates.

(D) Strains from C were induced for 5 h, lysed, and immunoblotted for MATR3 and 3-phosphoglycerate kinase (PGK; loading control). See also Figure S1.
mutations are found in the largely disordered regions of the protein, and clustered near the N-terminus and C-terminus (Figure 1A). Similarly in other ALS-associated RBPs including TDP-43, FUS, hnRNP A1, and hnRNP A2B1, pathogenic mutations are clustered in the disordered prion-like domains (PrLDs) (King et al., 2012; Taylor et al., 2016). Therefore, we next investigated if MATR3 contains prion-like character. Using the Prion-Like Amino Acid Composition algorithm (PLAAC) (Lancaster et al., 2014) we found that, unlike TDP-43 and FUS, MATR3 lacks a predicted PrLD (Figures 1B and S1).

TDP-43 and FUS are nuclear RNA-binding proteins with PrLDs that mislocalize to cytoplasmic inclusions in degenerating motor neurons of ALS patients (Robberecht and Philips, 2013; Taylor et al., 2016). Understanding of the molecular requirements driving aberrant LLPS and aggregation of these and other proteins, as well as modifiers of these properties, has been empowered by use of yeast model systems (Becker et al., 2017; Elden et al., 2010; Johnson et al., 2008, 2009; Ju et al., 2011; Outeiro and Lindquist, 2003; Sun et al., 2011). Therefore, we sought to investigate the toxicity and localization of MATR3 in yeast, which lack a MATR3 homolog. We inserted the human MATR3 sequence and a subset of ALS/FTD-linked MATR3 mutants into the centromeric pAG413GAL-ccdB vector (Alberti et al., 2007) under control of the tightly regulated galactose-inducible promoter, allowing for inducible expression and passaging without toxicity. We noted that MATR3WT was highly toxic when expressed in yeast, as were MATR3S85C, MATR3F115C, MATR3P154S, and MATR3T622A (Figure 1C). Thus, our yeast model recapitulates the highly toxic expression of wild-type MATR3 that has been observed in primary neurons and Drosophila models (Malik et al., 2018; Ramesh et al., 2020; Zhao et al., 2020). We do not observe a subtle increase in toxicity upon expression of the MATR3 mutants similar to that observed in primary neurons (Malik et al., 2018), which is likely due to the already very high toxicity of the wild-type protein in yeast. We also plated these strains on a mixture of sucrose with galactose to decrease MATR3 expression levels, and consequently toxicity, but still did not observe enhanced toxicity of the MATR3 mutants. Overall, the similarities we observe upon expression of MATR3 between yeast and primary neurons suggest that yeast can be used as a simple, yet relevant, model to study MATR3 misfolding.

We next aimed to better understand if MATR3 functions as a prion in yeast. Endogenous yeast prions are regulated by the native AAA+ ATPase Hsp104, which is required for yeast prion propagation and toxicity (Krobitsch and Lindquist, 2000; Parsell et al., 1994; Patino et al., 1996; Satpute-Krishnan et al., 2007). It has been shown that expression of a fragment of the huntingtin protein harboring a polyglutamine expansion is toxic in yeast, but RNQ+ and the prion disaggregase Hsp104 (Duenwald et al., 2006; Krobitsch and Lindquist, 2000). We therefore tested the dependence of MATR3 toxicity on Hsp104 by comparing toxicity of MATR3 in W303WT and W303Δhsp104 yeast strains (Figure 1C). MATR3 toxicity was similar in both strains, indicating that the presence of Hsp104 and its prion propagation activity does not modulate MATR3 toxicity. Despite the presence of a PrLD, TDP-43 and FUS toxicity in yeast is also independent of Hsp104 (Jackrel et al., 2014; Johnson et al., 2008). Although TDP-43 and FUS are not known to function as yeast prions, these PrLDs are thought to be crucial in regulating their role in LLPS (Franzmann and Alberti, 2019; Sprunger and Jackrel, 2021). Using immunoblotting, we confirmed consistent MATR3 protein expression in each of the strains (Figure 1D). Thus, we conclude that our yeast system can be used as a relevant model to study MATR3 toxicity in a highly tractable manner.

MATR3 forms nuclear puncta in yeast

To further study the properties of MATR3 in yeast, we used fluorescence microscopy. Here, we employed the pAG423GAL-ccdB-GFP plasmid to drive higher levels of MATR3 expression and to append a C-terminal GFP tag for visualization. We first confirmed that toxicity was similar to that of the untagged constructs (Figures 1 and 2A), and that expression levels were similar across the strains (Figure 2B). We observed that MATR3WT-GFP formed multiple round puncta in the nuclei (Figure 2C), which appear similar to the nuclear staining reported upon MATR3 expression in Drosophila, primary neurons, and mammalian cells (Gallego-Iradi et al., 2015, 2019; Malik et al., 2018; Ramesh et al., 2020). For MATR3S85C, we again observed accumulation of multiple foci, but these appeared less round than the MATR3WT puncta, and were not fully restricted to the nucleus. Similar irregularities were observed in the shape of MATR3F115C and MATR3T622A foci, while MATR3P154S puncta were more round, similar to those of MATR3WT. To analyze these puncta more closely, we imaged these cells using confocal microscopy. We again observed that MATR3 formed round puncta, while MATR3S85C, MATR3F115C, and MATR3T622A puncta appeared misshapen (Figure 2D). We quantified the differences in foci shapes by calculating the circularity ratio of each focus (Figure 2E). We found that MATR3S85C, MATR3F115C, and MATR3T622A all had significantly lower circularity ratios than
MATR3<sup>WT</sup>, indicating that their puncta are less round. This effect was most notable for MATR3<sup>S85C</sup>, and least severe for MATR3<sup>F115C</sup>. MATR3<sup>F115C</sup> puncta showed no significant difference in circularity ratio as compared to MATR3<sup>WT</sup>, supporting recent studies suggesting that this mutation does not significantly perturb MATR3 and, therefore, it may not be a causative mutation in ALS/FTD (van Bruggen et al., 2021). The rounded appearance of the MATR3<sup>WT</sup> puncta suggests that these structures may be dynamic liquid-like condensates. The misshapen puncta of MATR3<sup>S85C</sup>, MATR3<sup>P154S</sup>, and MATR3<sup>T622A</sup> that we observe may be due to perturbed phase separation, perhaps reflecting decreased dynamics within the puncta and conversion to a gel- or solid-like state.

**MATR3 mutations impair condensate dynamics**

To investigate the effect of MATR3 mutations on condensate properties, we performed fluorescence recovery after photobleaching (FRAP) experiments with a superresolution microscope (Figure 3A). When studying the round puncta of MATR3<sup>WT</sup> and MATR3<sup>F115C</sup> at this higher resolution, we observe that these spherical droplets appear devoid of MATR3 in the center (Figure 3A, pre-bleach images). These structures are reminiscent of the
LLPS intranuclear anisosomes, or shell-like spherical condensates, that form from RNA binding-deficient TDP-43 (Yu et al., 2021), which can also appear as “bubbles” (Schmidt and Rohatgi, 2016) or nuclear bodies (Wang et al., 2020). Further examination of MATR3WT-GFP cells confirmed that most of the puncta we observe are these spherical shell-like structures, which are also devoid of MATR3 in the center (Figures 3B and 3C). Likely these structures form because MATR3, and presumably some of its binding partners, are normally absent from yeast and so expression of MATR3 in yeast mimics an RNA-binding deficient state. In contrast to MATR3WT puncta, MATR3S85C, MATR3P154S, and MATR3T622A puncta appear to be misshapen and do not have a shell-like structure devoid of MATR3 in the center (Figure 3A, pre-bleach images). On monitoring the recovery of these structures after photobleaching, we observe rapid recovery of the MATR3WT structures, which fully recover by 60 s (Figure 3A). Similarly, we observe partial recovery of MATR3F115C shells within 2 min following photobleaching. However, no recovery was observed after photobleaching MATR3S85C, MATR3P154S, or MATR3T622A (Figure 3A and Video S1). We were unable to quantify recovery due to movement of the structures within the immobilized cells (Video S1). These results confirm our findings from the circularity measurements, and support our hypothesis that MATR3WT puncta are dynamic liquid-like droplets. MATR3F115C puncta are also liquid-like condensates but with slightly impaired dynamics as compared to MATR3WT. The more notably impaired dynamics characteristic of MATR3S85C, MATR3P154S, and MATR3T622A indicate that these proteins have undergone an aberrant phase transition to a gel- or solid-like structure. Importantly our studies are, to our knowledge, the first to show that disease-associated mutations in MATR3 can impair condensate dynamics in the full-length protein.

MATR3 displays decreased solubility in yeast

MATR3S85C has been shown to form insoluble, detergent-resistant accumulations in lymphoblasts, HEK293T cells, primary neurons, and Drosophila while MATR3WT is similarly insoluble under thermal or...
proteotoxic stress conditions (Hayes et al., 2020; Johnson et al., 2014; Malik et al., 2018; Ramesh et al., 2020; Senderek et al., 2009; Xu et al., 2012). We therefore assessed the solubility of MATR3WT and MATR3 mutants in yeast. Here, we performed semi-denaturing detergent-agarose gel electrophoresis (SDD-AGE) with the indicated SDS concentrations. MATR3 was detected via immunoblotting against GFP (mouse).

We performed SDD-AGE on yeast lysates under native conditions from strains expressing MATR3WT and its variants, including TDP-43-YFP and a polyglutamine expansion (103Q-YFP) as controls (Figure 4A). As has been shown previously, the polyglutamine lysate shows a characteristic smear in the upper portion of the gel, indicative of higher MW, insoluble species (Halfmann and Lindquist, 2008). TDP-43 displays a faint smear in a region of soluble, lower MW species than polyglutamine. MATR3 and each of the variants all displayed soluble, low MW smears similar to that of TDP-43. We also perform these assays with both 0 and 1% SDS (Figure 4B). In the absence of SDS, we find that TDP-43 forms insoluble accumulations that bind the CA membrane, while for a strain expressing GFP alone, little binding to the CA membrane is detected. Similar to the strain expressing TDP-43, we observe that MATR3WT and its variants bind heavily to the CA membrane. In the presence of 1% SDS, we observe very little binding to the CA membrane for any of the strains. We quantified these effects by calculating the ratio of protein bound to the CA versus NC membrane (Figure 4C). Compared to TDP-43-YFP, untagged GFP was significantly more soluble while MATR3WT and its variants were similarly soluble to TDP-43-YFP. We conclude that the solubility of MATR3WT and MATR3 variants is similar to that of TDP-43, and that pathogenic mutations to MATR3 do not significantly alter MATR3 solubility. While we do not observe differences in MATR3 solubility in the cells

To corroborate our results from the SDD-AGE assays, we also performed filter retention assays (Alberti et al., 2010). Here, cells are lysed with glass beads under native conditions. Extracts are then passed over a non-binding cellulose acetate (CA) membrane. Soluble proteins pass through this membrane while insoluble materials will bind the membrane. To account for total protein, extracts are passed in parallel over a nitrocellulose (NC) membrane. The membranes can then be probed by immunoblotting, and the ratio of protein bound to the CA to NC membranes is calculated. We again performed these assays with both 0 and 1% SDS (Figure 4B). In the absence of SDS, we find that TDP-43 forms insoluble accumulations that bind the CA membrane, while for a strain expressing GFP alone, little binding to the CA membrane is detected. Similar to the strain expressing TDP-43, we observe that MATR3WT and its variants bind heavily to the CA membrane. In the presence of 1% SDS, we observe very little binding to the CA membrane for any of the strains. We quantified these effects by calculating the ratio of protein bound to the CA versus NC membrane (Figure 4C). Compared to TDP-43-YFP, untagged GFP was significantly more soluble while MATR3WT and its variants were similarly soluble to TDP-43-YFP. We conclude that the solubility of MATR3WT and MATR3 variants is similar to that of TDP-43, and that pathogenic mutations to MATR3 do not significantly alter MATR3 solubility. While we do not observe differences in MATR3 solubility in the cells
We next confirmed expression of each MATR3 truncation construct by immunoblotting (Figure 5C). MATR3 typically runs approximately 30-40 kD higher than its calculated MW on SDS-PAGE, which we hypothesize is due to the highly acidic nature of its C-terminal region or post-translational modifications. We find that MATR3WT (123.7 kD calculated, 160 kD observed), MATR3(398–595), MATR3(398–847), and MATR3ΔNLS were slightly less toxic, while MATR3(1–575) displayed only subtle toxicity (Figure 5B). MATR3(1–397) and MATR3(576–847) were both nontoxic, indicating that the RRMs are required for toxicity. MATR3(398–595), which contains only the RRMs and NLS, is nearly as toxic as the full-length construct, while MATR3(1–575) lacks the NLS and is only subtly toxic, suggesting that both RNA binding and nuclear localization are required for MATR3 toxicity. Further, the N- and C-terminal regions of MATR3 do not contribute to toxicity. These results also help to explain why the pathogenic mutations which fall outside of the RRMs and NLS do not modulate MATR3 toxicity.

Next, we studied the localization and foci formation of strains expressing these constructs (Figures 5D–5F). Full-length MATR3 displayed multiple round nuclear foci as we previously observed (Figures 2C, 2D and 5D). MATR3(1–397), MATR3(1–575), and MATR3ΔNLS also drove accumulation of multiple foci per cell like the full-length construct, but unlike in the full-length construct, these foci were not restricted to the nucleus. This shift in localization is expected because all three of these constructs lack the NLS. However, MATR3(398–595), MATR3(398–847), and MATR3(576–847), which all contain the NLS identified by Malik et al., were all localized to the nucleus (Malik et al., 2018). Expression of the C-terminal constructs (MATR3(398–847) and MATR3(576–847)) both appeared to yield fewer foci per cell, with MATR3(576–847) accumulating almost exclusively in a diffuse nuclear pattern. Further, the patterns for MATR3(398–595) and MATR3(398–847) were highly similar, suggesting that the C-terminal region has little effect on foci formation. To confirm that these states represent distinct features, and that these puncta do not fuse or convert to a single larger structure, similar to the large puncta observed for MATR3(576–847), we imaged...
a subset of strains over a time course (Figure S2), but observed no such changes. Overall, these experiments demonstrate that the intrinsically disordered N-terminal region plays the biggest role in the formation of foci, driving accumulation of multiple foci per cell, while the RRMs also contribute to foci formation. However, MATR3(398–595), which lacks both the N- and C-terminal disordered regions, forms nuclear puncta. Our findings suggest that neither of these disordered regions is strictly required for foci formation. Further, MATR3 can be toxic when found in the nucleus or in the cytoplasm, although toxicity is greatest when MATR3 is restricted to the nucleus. In addition, aggregation alone is insufficient to drive toxicity.

To more carefully investigate the role of the two RRMs, we also tested constructs with 1, 2, or both RRMs deleted (Figure 5, constructs MATR3ΔRRM1, MATR3ΔRRM2, and MATR3ΔRRM1/2). We found that none of these constructs were toxic in yeast, confirming that the RRMs are largely responsible for MATR3 toxicity (Figure 5B). Importantly, while prior studies have suggested that RRM2 primarily drives toxicity (Gallego-Iradi et al., 2019; Malik et al., 2018; Ramesh et al., 2020), we find that ablation of either RRM entirely ablates toxicity. We confirmed expression of each deletion construct (Figure 5C). Surprisingly, expression of each of these RRM deletion constructs showed nearly all cells harbor a single nuclear focus with a spherical shell-like structure similar to those formed by MATR3WT and MATR3F115C (Figures 5D–5F). To investigate this further, we examined these cells using confocal microscopy and found that MATR3 lacking either or both RRMs coalesced into one large shell-like spherical structure per nucleus, as compared to the multiple smaller shell-like structures observed for MATR3WT and MATR3F115C (Figures 5G and 5H). We therefore conclude that both RRMs are required for toxicity and that ablation of either RRM eliminates the formation of multiple nuclear puncta and drives coalescence into large shell-like structures. We hypothesize that yeast lack the ideal RNA binding partners for MATR3, allowing full-length protein to form these spherical condensates, and upon complete ablation of RNA binding via RRM deletion, these condensates coalesce into a single larger structure. Further, we note that the formation of shell-like condensates is not unique to TDP-43, and MATR3 also undergoes LLPS into large multiphasic shell-like condensates in the absence of RNA binding.

### Potentiated Hsp104 variants suppress Matrin-3 toxicity and foci formation

Hsp104 is a potent amyloid disaggregase that solubilizes functional prions in yeast (Glover and Lindquist, 1998; Parsell et al., 1994; Shorter, 2008). Hsp104 has been shown to have limited activity in solubilizing amyloid and amyloid-like substrates associated with human disease, including TDP-43, FUS, and α-synuclein (DeSantis et al., 2012; Jackrel et al., 2014; Jackrel and Shorter, 2014a, 2014b, 2015; Lo Bianco et al., 2008). However, we have demonstrated that Hsp104 can be re-engineered to yield potentiated variants that display robust remodeling activity against a range of substrates including TDP-43, FUS, α-synuclein and TAF15 (Castellano et al., 2015; DeSantis et al., 2012; Jackrel et al., 2014, 2014b, 2015; Lo Bianco et al., 2008). Furthermore, MATR3 can be toxic when found in the nucleus or in the cytoplasm, although toxicity is greatest when MATR3 is restricted to the nucleus. In addition, aggregation alone is insufficient to drive toxicity.

To confirm that these changes are not simply due to altered expression levels, we assessed expression of each strain by MATR3WT and each of the Hsp104 variants, and we observe consistent expression levels for each strain (Figure S2), but observed no such changes. Overall, these experiments demonstrate that the intrinsically disordered N-terminal region plays the biggest role in the formation of foci, driving accumulation of multiple foci per cell, while the RRMs also contribute to foci formation. However, MATR3(398–595), which lacks both the N- and C-terminal disordered regions, forms nuclear puncta. Our findings suggest that neither of these disordered regions is strictly required for foci formation. Further, MATR3 can be toxic when found in the nucleus or in the cytoplasm, although toxicity is greatest when MATR3 is restricted to the nucleus. In addition, aggregation alone is insufficient to drive toxicity.

We next analyzed the effects of the Hsp104 variants on formation of MATR3WT foci and localization using fluorescence microscopy. Here, we analyzed two of the strongest suppressors: Hsp104AS035 and Hsp104V426L, as well as one of the better characterized variants: Hsp104AS035. We find that MATR3WT forms nuclear foci that are not heavily modified by expression of Hsp104 (Figures 6C and 6D). However, upon carriers of these variants show decreased TDP-43 and FUS expression levels, though the stoichiometry of TDP-43 or FUS to Hsp104 variant was maintained (Jackrel et al., 2014; Jackrel and Shorter, 2014a, 2015). Importantly, we also observe decreased expression of the Hsp104 variants themselves, suggesting that the variants are active even when expressed at lower levels than Hsp104WT. These finding are consistent with previous studies with TDP-43 and FUS, where expression of potentiated Hsp104 variants decreased TDP-43 and FUS expression levels, though the stoichiometry of TDP-43 or FUS to Hsp104 variant was maintained (Jackrel et al., 2014; Jackrel and Shorter, 2014a). We observed decreased MATR3WT levels when MATR3WT is coexpressed with a potentiated variant. However, we also observe decreased expression of the Hsp104 variants themselves, suggesting that the variants are active even when expressed at lower levels than Hsp104WT. These findings are consistent with previous studies with TDP-43 and FUS, where expression of potentiated Hsp104 variants decreased TDP-43 and FUS expression levels, though the stoichiometry of TDP-43 or FUS to Hsp104 variant was maintained (Jackrel et al., 2014; Jackrel and Shorter, 2014a).
expression of Hsp104A503V, Hsp104A503S, or Hsp104V426L we observed an increase in the number of cells with just a single nuclear focus per cell (Figure 6C). We quantified these effects by counting the number of cells with one or more than one focus and found that there was a consistent increase in the number of cells with a single nuclear focus for each of the potentiated variants, although this trend was subtle (Figure 6D). We therefore conclude that potentiated Hsp104 variants are capable of suppressing MATR3WT toxicity and foci formation.

Finally, we tested if the potentiated Hsp104 variants could also suppress the toxicity of the MATR3 pathogenic variants. Here, we tested the same panel of Hsp104 variants against MATR3 WT, MATR3S85C, MATR3F115C, MATR3P154S, and MATR3T622A (Figure 6). Just as Hsp104 does not suppress the toxicity of MATR3, it also does not suppress the toxicity of the MATR3 variants (Figure 7A). However, the potentiated Hsp104 variants robustly suppress toxicity of each of the MATR3 variants tested. Hsp104A503S, Hsp104V426L, and...
Figure 7. Potentiated Hsp104 variants suppress the toxicity of MATR3 pathogenic mutants

(A) W303 Δhsp104 yeast were sequentially transformed with pAG423GAL-MATR3-GFP and vector, pAG416GAL-Hsp104, or the indicated variants. The strains were serially diluted 5-fold and spotted on glucose (non-inducing) or galactose (inducing) media. Scores are based on number of spots from an average of at least three replicates.

(B) Strains from A were induced for 5h, lysed, and immunoblotted for MATR3 (GFP, mouse), Hsp104, and PGK (loading control). Certain immunoblots were cropped to remove additional lanes for presentation purposes, and crop lines are marked with lines.

Table:

| Variant          | Score (Glucose) | Score (Galactose) |
|------------------|-----------------|-------------------|
| 2x Vector        | 4.5             | 2.5               |
| Vector           | 1.5             | 1.5               |
| Hsp104           | 1.0             | 1.5               |
| Hsp104:A503V     | 2.0             | 2.0               |
| Hsp104:A503S     | 2.5             | 2.5               |
| Hsp104:A503G     | 2.5             | 2.5               |
| Hsp104:V426L     | 2.5             | 2.5               |
| Hsp104:A437W     | 2.5             | 2.5               |
| Hsp104:N539K     | 2.5             | 2.5               |
| Hsp104:DPLF-A503V| 2.5             | 2.5               |

For MATR3:P154S-GFP:

| Variant          | Score (Glucose) | Score (Galactose) |
|------------------|-----------------|-------------------|
| 2x Vector        | 4.0             | 4.0               |
| Vector           | 1.0             | 1.0               |
| Hsp104           | 1.0             | 1.0               |
| Hsp104:A503V     | 2.0             | 2.0               |
| Hsp104:A503S     | 2.5             | 2.5               |
| Hsp104:A503G     | 2.5             | 2.5               |
| Hsp104:V426L     | 2.5             | 2.5               |
| Hsp104:A437W     | 2.5             | 2.5               |
| Hsp104:N539K     | 2.5             | 2.5               |
| Hsp104:DPLF-A503V| 2.5             | 2.5               |

For MATR3:T622A-GFP:

| Variant          | Score (Glucose) | Score (Galactose) |
|------------------|-----------------|-------------------|
| 2x Vector        | 4.5             | 4.5               |
| Vector           | 2.0             | 2.0               |
| Hsp104           | 2.0             | 2.0               |
| Hsp104:A503V     | 2.0             | 2.0               |
| Hsp104:A503S     | 2.5             | 2.5               |
| Hsp104:A503G     | 2.5             | 2.5               |
| Hsp104:V426L     | 2.5             | 2.5               |
| Hsp104:A437W     | 2.5             | 2.5               |
| Hsp104:N539K     | 2.5             | 2.5               |
| Hsp104:DPLF-A503V| 2.5             | 2.5               |
MATR3WT in patient samples and in primary neurons shows a nuclear granular pattern (Gallego-Iradi et al., 2018; Moloney et al., 2018; Ramesh et al., 2020; Zhang et al., 2019; Zhao et al., 2020). Staining for neurons, and mouse models also resulted in toxicity, shortened lifespan, and/or motor defects (Malik et al., 2018). Press MATR3, they do not have analogous RNA binding partners to those found in primary neurons, thereby allowing formation of these phase-separated condensates in yeast. To our knowledge, this is the first system in which MATR3 phase separation can be investigated with the full-length construct. Furthermore, we find that MATR3 does not form high MW species by SDD-AGE, similar to TDP-43. It remains unclear whether the lack of a prion-like domain can drive differences in aggregation and phase separation as compared to proteins with prion-like domains, such as TDP-43 and FUS.

While MATR3 is a largely disordered RBP, it is not predicted to have a prion-like domain such as those found in other disordered RBPs that underpin ALS/FTD including TDP-43 and FUS (King et al., 2012). While yeast require the disaggregase Hsp104 to regulate prions, we found that MATR3 toxicity in yeast is independent of Hsp104, similar to TDP-43 and FUS (Jackrel et al., 2014; Johnson et al., 2008). Furthermore, we find that MATR3 does not form high MW species by SDD-AGE, similar to TDP-43. It remains unclear whether the lack of a prion-like domain can drive differences in aggregation and phase separation as compared to proteins with prion-like domains, such as TDP-43 and FUS.

While we observe many similarities between MATR3WT and the ALS/FTD-associated MATR3 mutants, we find that a key distinction between these proteins is their capacity to undergo liquid-liquid phase separation. We observe the formation of dynamic nuclear shell-like condensates upon expression of MATR3WT, MATR3F115C, and RNA-binding deficient MATR3 germFree. MATR3WT yeast contains several of these structures within a single nucleus. Upon deletion of either RRM, these structures coalesce into a single larger condensate, suggesting that binding of RNA to MATR3 impairs MATR3 phase separation. We hypothesize that because yeast do not normally express MATR3, they do not have analogous RNA binding partners to those found in primary neurons, thereby allowing formation of these phase-separated condensates in yeast. To our knowledge, this is the first system in which MATR3 phase separation can be investigated with the full-length construct. Furthermore, we find that MATR3WT, MATR3F115C, and MATR3T622A each form gel- or solid-like puncta that are distorted and less dynamic as compared to the liquid-like spherical shell structures comprised of MATR3WT. Formation of these misshapen droplets confirms that the S85C, P154S, and T622A mutations each perturb the LLPS of MATR3, converting MATR3 from a liquid state to a gel- or solid-like state. Our findings are supported by previous work showing that MATR3S85C can impair condensate formation and dynamics (Malik et al., 2018; Mensch et al., 2018). Importantly, in our yeast system we can distinguish the properties of the wild-type protein as compared to the pathogenic mutants S85C, P154S, and T622A while F115C does not display similar defects. In some systems no differences are noted between these four mutants, although it was recently reported that in a mouse knock-in model, the F115C mutation did not elicit a disease phenotype (van Bruggen et al., 2021). Impairment of phase separation is emerging as a key feature of ALS/FTD pathology, and now appears to also be crucial in governing MATR3 pathology (Sprunger and Jackrel, 2021). It remains to be determined when MATR3 undergoes physiological LLPS, and which specific condensates MATR3 occupies.

Strikingly, deletion of either or both RRMs leads to the formation of a single large shell-like spherical structure in the nucleus of each cell. These structures resemble the recently discovered anisosome condensates.
which form upon ablation of RNA-binding in TDP-43 (Yu et al., 2021). Because these multiphasic condensates are conserved among multiple RBPs, and have been linked to chaperone proteins (Yu et al., 2021), these structures may be a crucial aspect in the mechanism mediating recovery from cellular stress. Formation of these structures suggests that MATR3 plays a role in scaffolding the condensates rather than being recruited as a client. Our results also suggest that both RRM1 and RRM2 are crucially important in MATR3 function, and that deletion of either RRM has similar effects. These results are in contrast to prior studies which suggested that RRM2 plays a more important role (Gallego-Iradi et al., 2019; Malik et al., 2018; Ramesh et al., 2020). Further investigation will be necessary to identify which physiological condensates MATR3 participates in, as well as the role of MATR3 within those condensates. It will also be important to identify the species within the MATR3 shell-like condensates, which may include Hsp70 which was identified in the core of TDP-43 anisosomes. Further, it will be important to better understand the role of these multiphasic condensates, and if these are a common structural element involved in LLPS beyond their role in MATR3 and TDP-43 (Schmidt and Rohatgi, 2016; Wang et al., 2020; Yu et al., 2021). The mechanism by which MATR3 RRM domains mediate LLPS and toxicity remains unclear. It is plausible that sequestration of MATR3 to condensates buffers MATR3 toxicity or prevents aggregation of MATR3, thereby preventing MATR3 from sequestering other essential proteins.

To better understand the molecular determinants of MATR3 toxicity and foci formation as well as the contributions of its largely uncharacterized disordered regions, we generated a series of truncations and domain deletions of MATR3. We demonstrate that the minimal requirements for MATR3 toxicity are maintenance of the RRM and NLS. We determined that MATR3 proteotoxicity is primarily driven by its RRM, as toxicity is no longer observed upon deletion of either or both RRM. In future work, it will be important to confirm that this toxicity is directly driven by binding of RNA to the RRM. Alternatively, the folded RRM domains may provide crucial stabilization to an otherwise disordered protein, or mediate protein-protein interactions that drive MATR3 toxicity. We find that formation of multiple MATR3 foci is largely driven by the N-terminal disordered region, as constructs lacking this region form few or no foci. Together with our toxicity data, we conclude that MATR3 can be toxic in both the nucleus and the cytoplasm, though toxicity is greater when MATR3 is restricted to the nucleus. Further, aggregation alone is insufficient to drive toxicity.

We have also demonstrated that potentiated Hsp104 variants can suppress the toxicity of MATR3 and MATR3 mutants. These findings strongly support the idea that MATR3 toxicity is driven by corruption of proteostasis and protein misfolding, whether that be of MATR3 itself, or mediated by MATR3. We also demonstrate that potentiated Hsp104 variants decrease the number of MATR3 nuclear foci per cell. Importantly, the same Hsp104 variants which suppressed MATR3 toxicity have also been shown to suppress the toxicity, misfolding, and mislocalization of TDP-43 and FUS (Jackrel et al., 2014). Because multiple RBPs are known to aggregate in ALS/FTD, and they may behave synergistically, the solubilization of multiple RBPs by a single agent could have great therapeutic value. In this way, a single remodeling factor could be introduced to simultaneously reverse any toxic gain of function of misfolded MATR3, TDP-43, or FUS as well as any loss function due to misfolding of these RBPs.

Yeast models have been shown to be useful as highly tractable systems that can be leveraged to glean new insights into molecular determinants that drive aggregation and toxicity of proteins that misfold in disease (Elden et al., 2010; Johnson et al., 2008; Ju et al., 2011; Khurana and Lindquist, 2010; Sun et al., 2011). We have demonstrated that MATR3 proteinopathy implicated in myopathy, ALS, and FTD can be recapitulated in a novel yeast model system. Using our system, we have delineated key features driving MATR3 toxicity, aggregation, and LLPS. We anticipate that our system can be employed as a platform for rapid high-throughput screens to identify genetic or small molecule modifiers of MATR3 toxicity and aberrant LLPS. Our work has identified several potentiated Hsp104 variants which effectively suppress MATR3 toxicity, and these same variants can also reverse the proteotoxic misfolding of related proteins that drive ALS/FTD. In the future, it will be interesting to assess if these Hsp104 variants can antagonize proteotoxic misfolding in neuronal models of MATR3 proteinopathy.

Limitations of the study

Studies using a yeast model system cannot fully recapitulate all features of complex human disorders including ALS/FTD. Yet, they have been shown to be valuable systems for studying the features and malfunctioning of key genes that drive disease pathology (Couthouis et al., 2011, 2012; Elden et al., 2010; Johnson et al., 2008; Ju
et al., 2011; Kayatekin et al., 2018; Outeiro and Lindquist, 2003; Ryan et al., 2019; Sun et al., 2011; Tardiff et al., 2013; Treusch et al., 2011). Because yeast grow rapidly and are highly genetically tractable, larger numbers of constructs can be screened in yeast than is feasible in more complex model systems. It is also important to note that yeast do not naturally express MATR3. As a result, certain key RNA and protein binding partners may be absent, which could be the reason for the formation of shell-like condensates that form upon expression of MATR3WT and MATR3F115C. However, this limitation can also be viewed as a benefit of this system, because impaired RNA binding is thought to underpin ALS/FTD. Further, this allows for the liquid-liquid phase separation of MATR3 to be studied in a system using the full-length protein. In more complex model systems, LLPS studies of MATR3 have been restricted to use of constructs lacking the RRMs, resulting in deletion of nearly all of the folded regions of MATR3 (Malik et al., 2018). As a result, we suggest that it is important that a diverse range of model systems be employed to study MATR3.

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Yeast strains and media
- **METHOD DETAILS**
  - Plasmids
  - Yeast transformation and spotting assays
  - Immunoblotting
  - Fluorescence microscopy
  - Circularity ratio
  - Fluorescence recovery after photo bleaching
  - SDD-AGE and filter retention assay
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.isci.2022.103900.

ACKNOWLEDGMENTS

This work was supported by NIH grant F31NS120512 (to M.L.S), a WUSTL uSTAR Award (to K.L.), and a Target ALS Springboard Award, a Frick Foundation for ALS Research Award, ALS Association grants 20-IIA-529 and 18-IIA-408, and NIH grant R35GM128772 (to M.E.J.). We thank members of the Jackrel Lab for review of the manuscript. Confocal data were generated on a Zeiss LSM 880 Airyscan confocal microscope, which was purchased with support from the Office of Research Infrastructure Programs (ORIP), a part of the National Institutes of Health Office of the Director, under Grant OD021629.

AUTHOR CONTRIBUTIONS

Conceptualization and methodology, M.L.S. and M.E.J.; Investigation, validation, and resources, M.L.S., K.L., B.S.S., and M.E.J.; Writing, M.L.S. and M.E.J.; Supervision and project administration, M.E.J.; Funding Acquisition, M.L.S., K.L., and M.E.J.

DECLARATION OF INTERESTS

The authors declare no competing interests.
REFERENCES

Alberti, S., Gitler, A.D., and Lindquist, S. (2007). A suite of gateway cloning vectors for high-throughput genetic analysis in Saccharomyces cerevisiae. Yeast 24, 913–919.

Alberti, S., Halfmann, R., and Lindquist, S. (2010). Biochemical, cell biological, and genetic assays to analyze amyloid and prion aggregation in yeast. Methods Enzymol. 470, 709–734.

Becker, L.A., Huang, B., Bieri, G., Ma, R., Knowles, D.A., Jafar-Nejad, P., Messing, J., Kim, H.J., Soriano, A., Auburger, G., et al. (2017). Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544, 367–371.

Belgrader, P., Day, R., and Benesney, R. (1991). Molecular cloning of matrin 3. A 125-kilodalton protein of the nuclear matrix contains an extensive acidic domain. J. Biol. Chem. 266, 9893–9899.

Boehringer, A., Garcia-Mansfield, K., Singh, G., Bakkar, N., Pirrotte, P., and Bowser, R. (2017). ALS-associated mutations in matrin 3 alter protein-protein interactions and impede mRNA nuclear export. Sci. Rep. 7, 14529.

Castellano, L.M., Bart, S.M., Holmes, V.M., Weissman, D., and Shorter, J. (2015). Repurposing Hsp104 to antagonize seminal protein interactions and impede mRNA nuclear export. EMBO J. 34, 653–668.

Couthous, J., Hart, M.P., Erion, R., King, O.D., Diaz, Z., Nakaya, T., Ibrahim, F., Kim, H.J., Mojsilovic-Petrovic, J., Panossian, S., et al. (2012). Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum. Mol. Genet. 21, 2899–2911.

Couthous, J., Hart, M.P., Shorter, J., DeJesus-Hernandez, M., Erion, R., Cristano, R., Liu, A.X., Ramos, D., Jethava, N., Hosangadi, D., et al. (2011). A yeast functional screen predicts new candidate ALS disease genes. Proc. Natl. Acad. Sci. U S A 108, 20881–20890.

Deprez, F.F., Puckelwitz, M.J., Augustynowicz, A., Wolfgeher, D., Labno, C.M., Pierre-Louis, D., Cicka, D., Kron, S.J., Holaska, J., and McNally, E.M. (2015). Disruption of the lamin A and matrin-3 interaction by myopathic LMNA mutations. Hum. Mol. Genet. 24, 4284–4295.

DeSantis, M.E., Leung, E.H., Sweeny, E.A., Jackrel, M.E., Cushman-Nick, M., Neuhausen-Follins, A., Vashist, S., Sochor, M.A., Knight, M.N., and Shorter, J. (2012). Operational plasticity enables hsp104 to disaggregate diverse amyloid and nonamyloid clients. Cell 151, 778–793.

Duennewald, M.L., Jagadish, S., Giorgini, F., Muchowski, P.J., and Lindquist, S. (2006). A network of protein interactions determines polyglutamine toxicity. Proc. Natl. Acad. Sci. U S A 103, 11051–11056.

Elden, A.C., Kim, H.J., Hart, M.P., Chen-Plotkin, A.S., Johnson, B.S., Fang, X., Aramakol, M., Geser, F., Greene, R., Liu, M.M., et al. (2010). Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069–1075.

Fheit, H., Silberglett, A., Schneider, L.B., Gutierrez, J.A., Fitousi, R.P., Reyes, C., Rouleau, G.A., Brains, B., Jackson, C.E., Beckmann, J.S., et al. (1998). Vocal cord and pharyngeal weakness with autosomal dominant distal myopathy: clinical description and gene localization to 5q31. Am. J. Hum. Genet. 63, 1732–1742.

Franzmann, T.M., and Alberti, S. (2019). Prion-like low-complexity sequences: key regulators of protein solubility and phase behavior. J. Biol. Chem. 294, 7128–7136.

Galeglo-iradis, M.C., Clare, A.M., Brown, H.H., Janus, C., Lewis, J., and Shorter, J. (2020). Subcellular localization of matrin 3 containing mutations associated with ALS and distal myopathy. PLoS ONE 10, e0142144.

Galeglo-iradis, M.C., Strunk, H., Crown, A.M., Davila, R., Brown, H., Rodriguez-Lebron, E., and Borchert, D.R. (2019). N-terminal sequences in matrin 3 mediate phase separation into droplet-like structures that recruit TDP43 variants lacking RNA binding elements. Lab. Invest. 99, 1030–1040.

Gietz, R.D., and Schiestl, R.H. (2007). High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. Nat. Protoc. 2, 31–34.

Glover, J.R., and Lindquist, S. (1998). Hsp104, Hsp70, and Hsp40: a novel chaperone system that rescues previously aggregated proteins. Cell 94, 73–82.

Halfmann, R., and Lindquist, S. (2008). Screening for amyloid aggregation by semi-denaturing detergent-agarose gel electrophoresis. J. Vis. Exp. 17, e838.

Hayes, L.R., Duan, L., Bowen, K., Kalab, P., and Flannery, J.H. (2009). C9orf72 engineered repeat proteins disrupt karyopherin-mediated nuclear import. Elife 9, e15685.

Hibino, Y., Ohzeki, H., Sugano, N., and Hiraga, K. (2000). Transcription modulation by a rat nuclear scaffold protein, P130, and a rat highly repetitive DNA component or various types of animal and plant matrix or scaffold attachment regions. Biochem. Biophys. Res. Commun. 279, 282–287.

Iradi, M.C.G., Triplett, J.C., Thomas, J.D., Davila, R., Crown, A.M., Brown, H., Lewis, J., Swanson, M.S., Xu, G., Rodic-Lewis, E., et al. (2011). Characterization of gene regulation and protein interaction networks for Matrin 3 encoding mutations linked to amyotrophic lateral sclerosis and myopathy. Sci. Rep. 8, 4049.

Jackrel, M.E., DeSantis, M.E., Martinez, B.A., Castellano, L.M., Stewart, R.M., Caldwell, K.A., Caldwell, G.A., and Shorter, J. (2014). Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. Cell 156, 170–182.

Jackrel, M.E., and Shorter, J. (2014a). Repurposing Hsp104 to antagonize seminal protein interactions and impede mRNA nuclear export. Sci. Rep. 4, 1030–1040.

Johnson, B.S., McCaffery, J.M., Lindquist, S., and Gitler, A.D. (2008). A yeast TDP-43 proteinopathy model: exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc. Natl. Acad. Sci. U S A 105, 6439–6444.

Johnson, B.S., Snead, D., Lee, J.J., McCaffery, J.M., Shorter, J., and Gitler, A.D. (2009). TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J. Biol. Chem. 284, 20329–20339.

Johnson, J.O., Piro, E.P., Boehringer, A., Chia, R., Feit, H., Renton, A.E., Pliner, H.A., Abramzon, Y., Marangi, G., Winborn, B.J., et al. (2014). Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat. Neurosci. 17, 664–666.

Ju, S., Tarabff, D.F., Han, H., Diya, K., Zhang, Q., Maquat, L.E., Bosco, D.A., Hayward, L.J., Brown, R.H., Jr, Lindquist, S., et al. (2011). A yeast model of FUS/TLS-Dependent cytotoxicity. PLoS Biol. 9, e1001052.

Kao, C.S., van Bruggen, R., Kim, J.R., Chen, X.X.L., Chan, C., Lee, J., Cho, W.I., Zhao, M., Arndt, C., Maksmovic, K., et al. (2020). Selective neuronal degeneration in MATR3 S85C knock-in mouse model of early-stage ALS. Nat. Commun. 11, 5304.

Kayatekin, C., Amasino, A., Gaglia, G., Flannick, J.M., Fanning, S., Narayan, P., Borsa, M.I., Pincus, D., Landgraf, D., et al. (2018). Translocon docker Ste24 protects against JAPP oligomer-induced proteotoxicity. Cell 173, 62–73 e69.

Khurana, V., and Lindquist, S. (2010). Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with baker’s yeast? Nat. Rev. Neurosci. 11, 436–449.

Kim, H.J., Kim, N.C., Wang, Y.D., Scarborough, E.A., Moore, J., Diaz, Z., Maclea, K.S., Freibbaum, B., Li, S., Molliex, A., et al. (2013). Mutations in prion-like domains in hnRNP2B1 and hnRNP A1 cause multisystem proteinopathy and ALS. Nature 495, 467–473.

King, O.D., Gitler, A.D., and Shorter, J. (2012). The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 1462, 61–80.

Krobitsch, S., and Lindquist, S. (2000). Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the neurodegenerative disease-linked proteins. Dis. Model Mech. 7, 1175–1184.
expression of chaperone proteins. *Proc. Natl. Acad. Sci. U S A* 97, 1589–1594.

Kwiatkowski, T. J., Jr., Bosco, D. A., Leclerc, A. L., Tamraza, E., Vanderburg, C. R., Russ, C., Davis, A., Gilchrist, J., Kasarskis, E. J., Munsat, T., et al. (2009). Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205–1208.

Lancaster, A. K., Nutter-Upham, A., Lindquist, S., and King, O. D. (2014). PLAAC: a web and command-line application to identify proteins with prion-like amino acid composition. Bioinformatics 30, 2501–2502.

Leblond, C. S., Gan-Or, Z., Spiegelman, D., Laureen, S., Szuto, A., Hodgkinson, A., Dionne-Laporte, A., Provencher, P., de Carvalho, M., Orrú, S., et al. (2016). Replication study of MATR3 in familial and sporadic amyotrophic lateral sclerosis. Neurobiol. Aging 37, 209.e217–209.e221.

Leonard, D., Ajuh, P., Lamond, A. I., and Legerski, R. J. (2003). Hsp104/HsFL2 interacts with CDCA5 and is involved in pre-mRNA splicing. Biochem. Biophys. Res. Commun. 308, 793–801.

Lin, K.-P., Tsai, P.-C., Liao, Y.-C., Chen, W.-T., Tsai, C.-P., Soong, B.-W., and Lee, Y.-C. (2015). A novel Arg147Trp mutation in the gene encoding the nuclear matrix domain. Protein Sci. 24, 2375–2389.

Lo Bianco, C., Shorter, J., Regulier, E., Lashuel, H., Quintero-Rivera, F., Xi, Q.J., Keppler-Noreuil, J., Thompson, M.L., Chung, C.Y., Kamadurai, H.B., Tardiff, D.F., Jui, N.T., Khurana, V., Tambe, M.A., Sweeny, E.A., Jackrel, M.E., Go, M.S., Sochor, S., and Razzo, B.M., DeSantis, M.E., Gupta, K., and Sussman, J.L. (2005). FoldIndex: a simple tool to predict whether a given protein sequence overexpressing wild-type and ALS-linked mutant MATR3. Acta Neuropathol. Commun. 6, 137.

Nara, P., Padhi, A.K., Dave, U., Mishra, D., Bhatia, R., Vivekanandan, P., and Gomes, J. (2019). Identification and characterization of novel and rare susceptible variants in Indian amyotrophic lateral sclerosis patients. Neurogenetics 20, 197–208.

Neumann, M., Bentmann, E., Dormann, D., Jawaid, A., DeJesus-Hernandez, M., Ansonge, O., Roeber, S., Kretzschmar, H.A., Munoz, D.G., Kusaka, H., et al. (2011). FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain 134, 2595–2609.

Neumann, M., Sampathu, D.M., Kwong, L.K., Trax, A.C., Micsenyi, M.C., Chou, T.T., Bruce, J., Schuck, T., Grossman, M., Clark, C.M., et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130–133.

Ongorie, P., Verdiani, S., Bandettini Di Poggio, M., Zuccarino, R., Vignolo, M., Caponetto, C., and Mandich, P. (2015). A novel Arg147Trp mutation in the gene encoding the nuclear matrix domain. Protein Sci. 24, 671–675.

Outeiro, T.F., and Lindquist, S. (2003). Yeast cells provide insight into alpha-synuclein biology and pathology. Science 302, 1772–1775.

Parsi, D.A., Kовал, A.S., Singer, M.A., and Lindquist, S. (1994). Protein disaggregation mediated by heat-shock protein Hsp104. Nature 372, 475–478.

Patino, M.M., Liu, J.J., Glover, J.R., and Lindquist, S. (1996). Support for the prion hypothesis for inheritance of a phenotypic trait in yeast. Science 273, 622–626.

Prilusky, J., Felder, C.E., Zeev-Ben-Mordehai, T., Roos, A., Elbracht, M., Stendel, C., Tourney, L., Mikhailova, V., et al. (2009). Autosomal-dominant distal myopathy associated with a recurrent missense mutation in the gene encoding the nuclear matrix protein, matrin 3. Am. J. Hum.Genet. 84, 511–518.

Shorter, J. (2008). Hsp104: a weapon to combat diverse neurodegenerative disorders. Neurosignals 16, 63–74.

Sprunger, M.L., and Jackrel, M.E. (2021). Prion-like proteins in phase separation and their link to disease. Biomolecules 11, 1014.

Sun, Z., Diaz, Z., Fang, X., Hart, M.P., Chesi, A., Shorter, J., and Gitler, A.D. (2011). Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. iScience 17, 671–675.

Sweeney, E.A., Jackrel, M.E., Go, M.S., Sochor, M.A., Razo, B.M., DeSantis, M.E., Gupta, K., and Shorter, J. (2015). The hsp104 N-terminal domain enables disaggregate plasticity and potentiation. Mol.Cell 57, 836–849.

Tada, M., Doi, H., Koyano, S., Kubota, S., Fukai, R., Hashiguchi, S., Hayashi, N., Kawamoto, Y., Kunii, M., Tanaka, K., et al. (2018). Matrin 3 binds and stabilizes mRNA. PLoS ONE 6, e23882.

Salton, M., Elkon, R., Borodina, T., Davydov, A., Yasp, M.-L., Halpern, E., and Shiloh, Y. (2011). Matrin 3 binds and stabilizes mRNA. PLoS ONE 6, e23882.

Salton, M., Lenthal, Y., Wang, S.-Y., Chen, D.J., and Shiloh, Y. (2010). Involvement of Matrin 3 and SFPQ/NONO in the DNA damage response. Cell Cycle 9, 1568–1576.

Sanchez, Y., and Lindquist, S.L. (1990). HSP104 required for induced thermostolerance. Science 248, 1112–1115.

Satpute-Krishnan, P., Langseth, S.X., and Serio, T.R. (2007). Hsp104-dependent remodeling of prion complexes mediates protein-only inheritance. PLoS Biol. 5, e24.
Tariq, A., Lin, J., Jackrel, M.E., Hesketh, C.D., Carman, P.J., Mack, K.L., Weitzman, R., Gambogi, C., Hernandez Murillo, O.A., Sweeny, E.A., et al. (2019). Mining disaggregase sequence space to safely counter TDP-43, FUS, and alpha-synuclein proteotoxicity. Cell Rep. 28, 2080–2095.

Tariq, A., Lin, J., Noll, M.M., Torrente, M.P., Mack, K.L., Murillo, O.H., Jackrel, M.E., and Shorter, J. (2018). Potentiating Hsp104 activity via phosphomimetic mutations in the middle domain. FEMS Yeast Res. 18, foy042.

Taylor, J.P., Brown, R.H., Jr., and Cleveland, D.W. (2016). Decoding ALS: from genes to mechanism. Nature 539, 197–206.

Treusch, S., Hamamichi, S., Goodman, J.L., Matlack, K.E.S., Chung, C.Y., Shulman, J.M., Parrado, A., Bevis, B.J., Valastyan, J.S., et al. (2011). Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer’s disease risk factors in yeast. Science 334, 1241–1245.

Tsai, W.-H. (1985). Moment-preserving thresholding: a new approach. Computer Vis. Graphics Image Process. 29, 377–393.

van Bruggen, R., Maksimovic, K., You, J., Tran, D.D., Lee, H.J., Khan, M., Kao, C.S., Kim, J.R., Cho, W., Chen, X.X.L., et al. (2021). MATR3 F115C knock-in mice do not exhibit motor defects or neuropathological features of ALS. Biochem. Biophys. Res. Commun. 568, 48–54.

Vance, C., Rogelj, B., Hortobágyi, T., De Vos, K.J., Nishimura, A.L., Sreedharan, J., Hu, X., Smith, B., Ruddy, D., Wright, P., et al. (2009). Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208–1211.

Wang, C., Duan, Y., Duan, G., Wang, Q., Zhang, K., Deng, X., Qian, B., Gu, J., Ma, Z., Zhang, S., et al. (2020). Stress induces dynamic, cytotoxicity-antagonizing TDP-43 nuclear bodies via paraspeckle LncRNA NEAT1-mediated liquid-liquid phase separation. Mol. Cell 79, 443–458.e447.

Xu, G., Stevens, S.M., Jr., Kobeissy, F., Brown, H., McClung, S., Gold, M.S., and Borchelt, D.R. (2012). Identification of proteins sensitive to thermal stress in human neuroblastoma and glioma cell lines. PLoS ONE 7, e49021.

Xu, L., Li, J., Tang, L., Zhang, N., and Fan, D. (2016). MATR3 mutation analysis in a Chinese cohort with sporadic amyotrophic lateral sclerosis. Neurobiol. Aging 38, 218.e213–218.e214.

Yasuda, K., Clatterbuck-Soper, S.F., Jackrel, M.E., Shorter, J., and Mili, S. (2017). FUS inclusions disrupt RNA localization by sequestering kinesin-1 and inhibiting microtubule detyrosination. J. Cell Biol. 216, 1015–1034.

Yu, H., Lu, S., Gasior, K., Singh, D., Vazquez-Sanchez, S., Tapia, O., Toprani, D., Beccari, M.S., Yates, J.R., Da Cruz, S., et al. (2021). HSP70 chaperones RNA-free TDP-43 into anisotropic intranuclear liquid spherical shells. Science 371, eabb4309.

Zeitz, M.J., Malyavantham, K.S., Seifert, B., and Berezney, R. (2009). Matrin 3: chromosomal distribution and protein interactions. J. Cell Biochem. 108, 125–133.

Zhang, X., Yamashita, S., Hara, K., Doki, T., Tawara, N., Ikeda, M., Misumi, Y., Zhang, Z., Matsuo, Y., Nagai, M., et al. (2019). A mutant MATR3 mouse model to explain multisystem proteinopathy. J. Pathol. 249, 182–192.

Zhao, M., Kao, C.S., Arndt, C., Tran, D.D., Cho, W.I., Maksimovic, K., Chen, X.X.L., Khan, M., Zhu, H., Qiao, J., et al. (2020). Knockdown of genes involved in axonal transport enhances the toxicity of human neuromuscular disease-linked MATR3 mutations in Drosophila. FEBS Lett. 594, 2800–2818.
# STAR★METHODS

## KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|----------------------|--------|------------|
| Antibodies           |        |            |
| Rabbit polyclonal anti-Hsp104 | Enzo | ADI-SPA-1040 |
| Mouse monoclonal anti-PGK | Invitrogen | 459250 |
| Rabbit monoclonal anti-MATR3 N-terminus | Abcam | Ab151739 |
| Rabbit polyclonal anti-GFP | Sigma | G1544 |
| Mouse monoclonal anti-GFP | Roche | 1184-460-001 |
| Goat anti-rabbit secondary antibody | Li-cor | 926-68071 |
| Goat anti-mouse secondary antibody | Li-cor | 926-32210 |
| Bacterial and virus strains |        |            |
| XL10-Gold cells | Agilent | 230245 |
| One Shot TOP10 Chemically competent E. coli | Invitrogen | C404010 |
| Chemicals, peptides, and recombinant proteins |        |            |
| PfuUltra II Fusion HS DNA Polymerase | Agilent | 600672 |
| DpnI | New England Biolabs | R0176S |
| BP clonase | Invitrogen | 11789020 |
| LR clonase | Invitrogen | 11791020 |
| Experimental models: Organisms/strains |        |            |
| S. cerevisiae: W303a (MATA, can1-100, his3-11, 15, leu2-3, 112, trp1-1, ura3-1, ade2-1) | Schirmer et al. (2004) | N/A |
| S. cerevisiae: W303aΔhsp104 (MATA, can1-100, his3-11, 15, leu2-3, 112, trp1-1, ura3-1, ade2-1, hsp104::KanMX) | Schirmer et al. (2004) | N/A |
| S. cerevisiae: W303aΔhsp104-pAG303GAL-TDP-43-YFP | Aaron Gitler | N/A |
| S. cerevisiae: W303a-pAG303GAL-FLAG-103Q-GFP | James Shorter | N/A |
| Recombinant DNA |        |            |
| MATR3 cDNA | Dharmacon | MHS6278-202757255 |
| pDONR221-ccdB | Invitrogen | 12536017 |
| pAG416GAL-ccdB | Alberti et al. (2007) | N/A |
| pAG413GAL-ccdB | Alberti et al. (2007) | N/A |
| pAG423GAL-ccdB-EGFP | Alberti et al. (2007) | N/A |
| pAG303GAL-ccdB-EGFP | Alberti et al. (2007) | N/A |
| pDONR-221-MATR3 WT | This paper | N/A |
| pDONR-221-MATR3:S85C | This paper | N/A |
| pDONR-221-MATR3:F115C | This paper | N/A |
| pDONR-221-MATR3:P154S | This paper | N/A |
| pDONR-221-MATR3:T622A | This paper | N/A |
| pDONR-221-MATR3 WT (no stop codon) | This paper | N/A |
| pDONR-221-MATR3:S85C (no stop codon) | This paper | N/A |
| pDONR-221-MATR3:F115C (no stop codon) | This paper | N/A |
| pDONR-221-MATR3:P154S (no stop codon) | This paper | N/A |

(Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Meredith Jackrel (mjackrel@wustl.edu).

Materials availability
Plasmids newly generated in this study will be made readily available to the scientific community. Material transfers will be made with no more restrictive terms than in a Materials Transfer Agreement.

Continued

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| pDONR-221-MATR3:T622A (no stop codon) | This paper | N/A |
| pAG413GAL-MATR3 WT | This paper | N/A |
| pAG413GAL-MATR3:S85C | This paper | N/A |
| pAG413GAL-MATR3:F115C | This paper | N/A |
| pAG413GAL-MATR3:P154S | This paper | N/A |
| pAG413GAL-MATR3:T622A | This paper | N/A |
| pAG423GAL-MATR3-eGFP | This paper | N/A |
| pAG423GAL-MATR3:S85C-eGFP | This paper | N/A |
| pAG423GAL-MATR3:F115C-eGFP | This paper | N/A |
| pAG423GAL-MATR3:P154S-eGFP | This paper | N/A |
| pAG423GAL-MATR3:T622A-eGFP | This paper | N/A |
| pDONR-221-MATR3(1-397) | This paper | N/A |
| pDONR-221-MATR3(1-575) | This paper | N/A |
| pDONR-221-MATR3(398-595) | This paper | N/A |
| pDONR-221-MATR3(398-847) | This paper | N/A |
| pDONR-221-MATR3(576-847) | This paper | N/A |
| pAG423GAL-MATR3(1-397)-eGFP | This paper | N/A |
| pAG423GAL-MATR3(1-575)-eGFP | This paper | N/A |
| pAG423GAL-MATR3(398-595)-eGFP | This paper | N/A |
| pAG423GAL-MATR3(398-847)-eGFP | This paper | N/A |
| pAG423GAL-MATR3(576-847)-eGFP | This paper | N/A |
| pAG423GAL-MATR3(1-397), D496-575-eGFP | This paper | N/A |
| pAG416GAL-Hsp104 | Jackrel et al. (2014) | N/A |
| pAG416GAL-Hsp104:A503V | Jackrel et al. (2014) | N/A |
| pAG416GAL-Hsp104:A503S | Jackrel et al. (2014) | N/A |
| pAG416GAL-Hsp104:A503G | Jackrel et al. (2014) | N/A |
| pAG416GAL-Hsp104:V426L | Jackrel et al. (2014) | N/A |
| pAG416GAL-Hsp104:A437W | Jackrel et al. (2014) | N/A |
| pAG416GAL-Hsp104:N539K | Jackrel et al. (2014) | N/A |
| pAG416GAL-Hsp104:Y257F-A503V-Y662F | Jackrel et al. (2014) | N/A |

Software and algorithms

| Image J | Schneider et al. (2012) | https://imagej.nih.gov/ij/ |
| GraphPad Prism | GraphPad | Version 9.0 |
Data and code availability
All data reported in this paper will be shared by the lead contact upon request.

This paper does not report original code.

Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Yeast strains and media
All yeast were WT W303a (MATa; can1-100; his3-11,15; leu2-3,112; trp1-1; ura3-1; ade2-1) or the isogenic strain W303Δhsp104 (Sanchez and Lindquist, 1990). Yeast were grown in rich medium (yeast extract, peptone, dextrose (YPD)) or in synthetic media lacking the appropriate amino acids. Media was supplemented with 2% glucose, raffinose, or galactose. W303Δhsp104-pAG303GAL-TDP-43-YFP and W303WT-pAG303GAL-FLAG-103Q-GFP were provided by Dr. Aaron Gitler and Dr. James Shorter, respectively.

METHOD DETAILS

Plasmids
Human MATR3 cDNA was obtained from Dharmacon (MHS6278-202757255) and inserted into pDONR221-ccdB via Gateway BP reaction. The entry clone was used to transfer MATR3 to suitable yeast expression vectors (pAG413GAL-ccdB, pAG423GAL-ccdB-eGFP, pAG303GAL-ccdB-eGFP). MATR3 mutations were generated using Quikchange site-directed mutagenesis (Agilent). Separate entry clones were generated by PCR to produce MATR3ΔNLS (amino acid residues 588-595), MATR3ΔRRM1 (amino acid residues 398-473 deleted), MATR3ΔRRM2 (amino acid residues 496-575 deleted), and MATR3ΔRRM1/2 (amino acid residues 398-473 and 496-575 deleted) in pDONR-221-ccdB. These truncations were then transferred to 423GAL-ccdB-eGFP by LR reaction. Deletion constructs MATR3ΔNLS (amino acid residues 588-595), MATR3ΔRRM1 (amino acid residues 398-473 deleted), MATR3ΔRRM2 (amino acid residues 496-575 deleted), and MATR3ΔRRM1/2 (amino acid residues 398-473 and 496-575 deleted) were generated using Quikchange site-directed mutagenesis (Agilent). All MATR3 constructs were confirmed by DNA sequencing. pAG416GAL-Hsp104 and potentiated variants were generated previously (Jackrel et al., 2014).

Yeast transformation and spotting assays
Yeast were transformed according to standard protocols using polyethylene glycol and lithium acetate (Gietz and Schiestl, 2007). In brief, the indicated yeast strains were grown to early log phase, harvested, and washed with sterile water. The yeast were then resuspended in a 360µL transformation mixture containing 33% polyethylene glycol 3350, 0.1M lithium acetate, and 0.1 mg boiled single-stranded salmon sperm DNA. The indicated MATR3 expression vectors were then added and mixtures were incubated at 42°C for 20 min. Yeast were then harvested, washed, and plated on appropriate dropout media. For strains harboring both MATR3 and Hsp104, MATR3 was transformed first, transformants were harvested from selective media, and strains were subsequently transformed with pAG416GAL-Hsp104 plasmids. W303Δhsp104-pAG303GAL-MATR3-GFP was generated by linearizing pAG303GAL-MATR3-GFP with NheI followed by transformation into W303Δhsp104. For spotting assays, yeast were grown to saturation overnight in raffinose-supplemented dropout media at 30°C. Cultures were normalized to A600nm = 0.5, 9 mL cells were harvested, treated in 0.1M lithium acetate, and 0.1 mg boiled single-stranded salmon sperm DNA. The indicated MATR3 expression vectors were then added and mixtures were incubated at 42°C for 20 min. Yeast were then harvested, washed, and plated on appropriate dropout media. For strains harboring both MATR3 and Hsp104, MATR3 was transformed first, transformants were harvested from selective media, and strains were subsequently transformed with pAG416GAL-Hsp104 plasmids. W303Δhsp104-pAG303GAL-MATR3-GFP was generated by linearizing pAG303GAL-MATR3-GFP with NheI followed by transformation into W303Δhsp104. For spotting assays, yeast were grown to saturation overnight in raffinose-supplemented dropout media at 30°C. Cultures were normalized to A600nm = 1.50, serially diluted 5-fold, and spotted in duplicate onto synthetic dropout media containing glucose or galactose. Plates were analyzed after 2-3 days of growth at 30°C. Each experiment was repeated with at least three independent transformations. Yeast growth on galactose plates were scored on a scale of 0-6 using half integers from no growth to full growth. The averages from all trials were rounded to the nearest half integer for reporting.

Immunoblotting
Yeast were grown overnight in raffinose supplemented media and then induced with galactose for 5h at 30°C. Cultures were normalized to A600nm = 0.5, 9 mL cells were harvested, treated in 0.1M NaOH for 5min at room temperature, and cell pellets were then resuspended into 1x SDS sample buffer and boiled for 3min. Lysates were cleared by centrifugation, separated by SDS-PAGE (4–20% gradient, BioRad), and transferred to a PVDF membrane. Membranes were blocked in Odyssey Blocking Buffer (LI-COR) for 1h at room temperature. Primary antibody incubations were performed at 4°C overnight. Membranes were
incubated in secondary antibodies for 1h at room temperature. Membranes were imaged using a LI-COR Odyssey FC Imaging system. Antibodies used: rabbit anti-MATR3N-terminus monoclonal (Abcam), rabbit anti-GFP polyclonal (Sigma Aldrich), mouse anti-GFP monoclonal (Roche Applied Science), rabbit anti-Hsp104 polyclonal (Enzo Life Sciences), mouse anti-PGK monoclonal (Invitrogen), and fluorescently labeled anti-mouse and anti-rabbit secondary antibodies (LI-COR).

**Fluorescence microscopy**
For fluorescence microscopy, the indicated strains were grown and induced as described above for immunoblotting. After a 5 h induction at 30°C, cultures were harvested, and live cells were treated with Hoechst dye to visualize the nuclei. Images were collected at 100x magnification using a Nikon Eclipse Te2000-E microscope, a Nikon A1 Confocal LSM, or a Zeiss LSM 880 Airyscan confocal microscope and processed using ImageJ software. All experiments were repeated at least three times, and representative images are shown. For quantification, at least one hundred cells were manually counted per strain per trial to quantify number of foci or localization of MATR3-GFP.

**Circularity ratio**
The circularity ratio is a measurement of how round an object appears, taken as the ratio of the object’s area to the area of a perfect circle with the same perimeter as the given object. A perfectly circular object has a ratio of one, while less circular objects trend towards a ratio of zero. The circularity ratio is calculated by:

\[
\text{Circularity ratio} = 4\pi \left( \frac{\text{Area}}{\text{Perimeter}^2} \right)
\]

Circularity ratios of foci were measured from deconvolved confocal slices by auto-thresholding in ImageJ using the Moments method (Tsai, 1985). The area and perimeter of each focus was measured, which was then used to calculate circularity ratio.

**Fluorescence recovery after photo bleaching**
For FRAP experiments, the indicated strains were grown and induced as described above for immunoblotting. After a 5 h induction at 30°C, cultures were harvested, and live cells were immobilized between a 4% low-temperature agarose pad and coverslip, which was then sealed with nail polish. Cells were imaged on a Zeiss LSM 880 Confocal Microscope with Airyscan operated by Zen Black using an alpha Plan-Apochromat 100x oil objective. A horizontal 1 x 25 pixel line was drawn across the center of the foci. After acquisition of five pre-bleach images, ROIs were photobleached using a 488nm laser at 70% power and a 405nm laser at 1% power for 50 iterations of 16µsec per pixel. Fluorescence recovery was monitored for 2min at 1.29 sec/frame after bleaching using the Airyscan detector. Images were deconvolved with a 6.9 Airyscan parameter.

Image analysis was conducted in FIJI. While the cells were immobilized in the agarose pad, movement of the foci within the cells precluded the data from quantitative analysis. A trial required that the recovery of the focus or lack thereof remained within the field of view for the duration of analysis. At least ten trials were acquired for each strain. Representative images are shown for one trial of each strain.

**SDD-AGE and filter retention assay**
The indicated strains were grown and induced as described above for immunoblotting. After a 5 h induction at 30°C, 5mL of cells at A600nm = 0.5 were harvested and washed with sterile water. The cell pellet volume was approximated and resuspended in a 5x volume of native lysis buffer (50mM HEPES, pH 7.5, 150mM NaCl, 2.5mM EDTA, 1% triton-X-100, 10mM BME, 0.1mM PMSF, 5µM peptatin A, 1% yeast protease inhibitor cocktail (Sigma)) and one volume of acid-washed glass beads. Lysis was completed by alternating 30s of vortexing with 30s recovery on ice for ten minutes. Cell debris was pelleted at 2000 xg for 5 min and supernatant was diluted with 2x sample buffer (80mM Tris-HCl, pH 6.8, 10% glycerol, 0.2% bromophenol blue) supplemented with 0-4% SDS as indicated for 1x final concentration.

For semi-denaturing detergent agarose gel electrophoresis (SDD-AGE) (Alberti et al., 2010; Halfmann and Lindquist, 2008), samples were resolved on a horizontal 1% agarose gel in 20mM Tris, 200mM glycine, and 0.1% SDS at 4°C. The gels were then transferred onto a PVDF membrane in a modified Mini Trans-Blot cell at 4°C. Proteins were detected by immunoblotting as described above.
For filter retention assays (Alberti et al., 2010), cellulose acetate (CA) membranes were washed in PBST and then placed on top of filter paper in a Minifold I 96-well spot-blot array system (GE). 30 μL of each prepared lysate was applied to the CA membrane in triplicate, drawn through the system, and then wells were washed with PBST. For nitrocellulose (NC) binding, samples were spotted in triplicate onto NC membranes. Membranes were allowed to dry, washed in PBST, blocked, and imaged by immunoblotting as described above. Bound protein was quantified using ImageStudio Lite software (LI-COR). For quantifying the amount of aggregated protein, the GFP signal of the CA membrane was divided by the GFP signal of the NC membrane and normalized to TDP-43-YFP. Four biological replicates were completed with three technical replicates per blot. Comparisons were made using a one-way ANOVA with a Dunnett’s multiple comparisons test.

QUANTIFICATION AND STATISTICAL ANALYSIS
As described in the figure legends, all data points in each graph are means ± standard error of the mean (SEM). For yeast experiments, n represents a biological replicate. For microscopy experiments, n represents a single cell. N is indicated in the figure legends. Statistical analysis was performed using a one-way ANOVA with a Dunnett’s multiple comparisons test. p-values are shown in the figure legends, with p > 0.05 designated as non-significant.